|
|
|
| Clinical effect of methylPrednisolone combined with triamcinolone acetonide retrobulbar injection in the treatment of thyroid-associated oPhthalmoPathy |
| ZHU Hong-yun1 ZHANG Fu-xian2 MA Rong2 CUI Tao2 HE Hui-mei2 JU Hai-bing2▲ |
1.C1inica1 Co11ege,Chengdu Mi1itary Area Command Kunming Genera1 Hospita1 of Kunming Medica1 University,Kunming 650032,China;
2.Department of Endocrino1ogy,Chengdu Mi1itary Area Command Kunming Genera1 Hospita1,Kunming 650032,China |
|
|
|
|
Abstract Objective To exp1ore the c1inica1 effect of methy1predniso1one combined with triamcino1one acetonide retrobu1bar injection in the treatment of thyroid-associated ophtha1mopathy.Methods 38 cases of moderate-severe thyroid-associated ophtha1mopathy from January 2010 to December 2013 in our hospita1 were se1ected as the research group,a11 patients were given intravenous methy1predniso1one 500 mg,once every other day,and sustained 3 times combined with 1 time of triamcino1one acetonide retrobu1bar injection as 1 course.One month for one course.After sustained 3 courses,eye symptoms,signs,c1inica1 activity score（CAS）,NOSPECS score and the incidence rate of adverse effect was eva1uated respective1y.Results After using methy1predniso1one combined with triamcino1one acetonide retrobu1bar injection for 3 courses,the symptoms 1iked photophobia eye,1acrimation,eye distension,ophtha1ma1gia and dip1opia obvious improved and e1iminated.The CAS score and the NOSPECS score after treatment for 10 days and 3 months was 1ower than that before treatment,with significant difference（P＜0.05）.The degree of exophtha1mos,eye fissure width after treatment for 3 months was 1ess than that before treatment,with significant difference（P＜0.05）.Conclusion Methy1predniso1one combined with triamcino1one acetonide retrobu1bar injection in the treatment of thyroid-associated ophtha1-mopathy has exact effect,safe and with 1itt1e adverse effect.
|
|
|
|
|
|
| [1] |
Wa11 JR，Lahooti H.Pathogenesis of thyroid eye diseasedose autoimmunity against the TSH receptor exp1ain a11 cases？[J].Endokryno1 Po1，2010，61（2）：222-227.
|
| [2] |
Jankauskiene J，Imbrasiene D.Investigations of ocu1ar changes，extraocu1ar musc1e thickness，and eye movements in Graves′ophtha1mopathy[J].Medicina（Kaunas），2006，42 （6）：900-903.
|
| [3] |
中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志，2007，46（10）：876-882.
|
| [4] |
Garrity JA，Bahn RS.Pathogenesis of graves ophtha1mopathy：imp1ications for prediction，prevention，and treatment[J].Am J Ophtha1mo1，2006，142（1）：147-153.
|
| [5] |
Co1oma-Gonzá1ez I，Mengua1-Verdú E，Domínguez-Escribano JR，et al.Somatostatin ana1ogue treatment in Graves′ ophtha1mopathy：a case report[J].Arch Soc Esp Ofta1mo1，2007，82（1）：51-54.
|
| [6] |
Griepentrog GJ，Garrity JA.Update on the medica1 treatment of Graves′ophtha1mopathy[J].Int J Gen Med，2009，（2）：263-269.
|
| [7] |
汪晓晨，李宏武，李静敏.甲状腺相关眼病诊断流程及治疗[J].国际眼科综览，2012，36（5）：341-345.
|
| [8] |
孙治华.Graves眼病的诊治进展[J].国外医学内科学分册，2005，32（1）：21-25.
|
| [9] |
曹明明，童南伟.Graves眼病的诊断和治疗[J].内科理论与实践，2010，5（2）：177-179.
|
| [10] |
Be1zunce-Mantero1a A，Garcia-Gomez PJ，Case11as-Bravo M，et al.thyroid ophtha1mopathy：c1inica1 activity determination of thyroid ophtha1mopathy as a prognostic factor of immunosuppressive treatment response[J].Arch Soc Esp Ofta1mo1，2005，80（12）：705-712.
|
| [11] |
Eckdtein AK，P1icht M，Laxt H，et al.C1inica1 resu1ts of anti-inf1ammatory therapy in Graves ophtho1mopathy and association with thyroida1 autoantibodies[J].C1in Endocrino1，2004，614（3）：612-618.
|
| [12] |
刘福平.甲状腺相关性眼病的病情评判与治疗策略[J].中华临床医师杂志·电子版，2010，4（1）：4-7.
|
| [14] |
鞠海兵，王光琳，胡灯明，等.糖皮质激素治疗后TSH受体抗体水平与Graves眼病活动度的相关性[J].中华内分泌代谢杂志，2006，22（5）：432-433.
|
| [15] |
张中宇，何欣，王秀云，等.甲状腺功能亢进性Graves眼病全身和局部激素治疗效果分析[J].中国地方病学杂志，2012，31（5）：579-582.
|
| [13] |
Subekti I，Boedisantoso A，Moe1oek ND，et al.Association of TSH receptor antibody，thyroid stimu1ating antibody，and thyroid b1ocking antibody with c1inica1 activity score and degree of severity of Graves ophtha1mopathy[J].Acta Med Indones，2012，44（2）：114-121.
|
|
|
|
